Research programme: tetrahydrofolate dehydrogenase inhibitors - Cloud Pharmaceuticals

Drug Profile

Research programme: tetrahydrofolate dehydrogenase inhibitors - Cloud Pharmaceuticals

Alternative Names: Anti-parasitic therapeutics - Cloud Pharmaceuticals; DHFR inhibitors - Cloud Pharmaceuticals; Dihydrofolate reductase inhibtors - Cloud Pharmaceuticals; pfDHFR inhibtor - Cloud Pharmaceuticals

Latest Information Update: 31 Jul 2014

Price : $50

At a glance

  • Originator Cloud Pharmaceuticals
  • Class
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Malaria

Most Recent Events

  • 14 Jul 2014 Early research in Malaria in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top